

ORAL PRESENTATION

Open Access

Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma

Aizea Morales-Kastresana^{1*}, Sanmamed F Miguel^{1,2}, Inmaculada Rodriguez², Asis Palazon¹, Ivan Martinez-Forero¹, Sara Labiano¹, Sandra Hervas-Stubbs¹, Bruno Sangro², Carmen Ochoa¹, Ana Rouzaut¹, Arantza Azpilikueta¹, Elixabet Bolaños¹, Maria Jure-Kunkel³, Ines Gutgemann⁴, Ignacio Melero¹

From Society for Immunotherapy of Cancer 28th Annual Meeting
National Harbor, MD, USA. 8-10 November 2013

Several immunostimulatory monoclonal antibodies (ISmAbs) that derepress and unleash antitumor immune responses are showing efficacy in cancer clinical trials. MAbs anti-B7-H1 (PD-L1) block a critical inhibitory pathway for T cells, while antibodies anti-CD137 and OX40 provide intense T cell costimulation. Documenting efficacy of immunotherapies on spontaneous tumors arising in oncogene transgenic mice is considered more predictive than experiments on transplanted tumors. A combination of these ISmAbs has been tested on a transgenic mouse model of spontaneous primary liver cancer in which c-myc drives transformation and the tumor cells express ovalbumin as a surrogate transgenic antigen. The induced tumor lymphocyte infiltrates and immune mechanisms of action were studied. The triple combination of mAbs clearly extended survival of mice bearing hepatocellular carcinomas (HCC) and synergized with adoptive T cell therapy with activated TCR-transgenic T cells that recognize OVA. Mice undergoing therapy showed a clear increase in the tumor tissue infiltration by activated and blastic CD8 T lymphocytes expressing the ISmAb-targeted receptors. The triple combination of ISmAbs did not result in enhanced OVA-specific CTL activity but other antigens in cell lines derived from such HCC were recognized by the elicited tumor infiltrating T lymphocytes. Indeed adoptive transfer of OT-1 cells to

tumor bearing mice resulted in their tolerization, unless the triple mAb therapy was instigated. Our results emphasize the role of combinational immunotherapy approaches including ISmAbs to impact on aggressive and highly T cell-tolerizing hepatocellular carcinomas.

Authors' details

¹CIMA, Pamplona, Spain. ²CUN, Pamplona, Spain. ³Bristol Myers Squibb, Lawrenceville, NJ, USA. ⁴University of Bonn, Bonn, Germany.

Published: 7 November 2013

doi:10.1186/2051-1426-1-S1-O7

Cite this article as: Morales-Kastresana et al.: Therapeutic activity of a combination of immunostimulatory monoclonal antibodies (anti-B7-H1, CD137 and OX40) on a c-myc-driven spontaneous transgenic model of hepatocellular carcinoma. *Journal for ImmunoTherapy of Cancer* 2013 1(Suppl 1):O7.

¹CIMA, Pamplona, Spain

Full list of author information is available at the end of the article